Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
Date:11/1/2007

available-for-sale totaled $61.7 million.

Recent Highlights

-- IND Accepted for ANA773. During the third quarter, Anadys filed an

Investigational New Drug Application (IND) to commence the clinical

investigation of ANA773 in cancer patients. The Food and Drug

Administration has accepted our IND and we expect to begin our first

clinical trial of ANA773 by the end of the year. ANA773, a novel oral

prodrug of a TLR7 agonist, has demonstrated favorable biologic activity

and promising pharmaceutical properties in preclinical studies.

-- Appointment of Steve Worland, Ph.D. as President and CEO. On

August 24, 2007, we announced that Steve Worland, Ph.D. had been

promoted to the position of President and Chief Executive Officer. Dr.

Worland was also appointed as a member of the Company's Board of

Directors. Dr. Worland joined Anadys in March 2001 as Chief Scientific

Officer and most recently served as President, Pharmaceuticals. Prior

to joining the Company, Dr. Worland was Vice President, Head of

Antiviral Research, at Agouron Pharmaceuticals, a Pfizer Company and

was also a Vice President at Warner-Lambert prior to its acquisition by

Pfizer.

-- Discontinuation of ANA975 Development and Strategic Restructuring of

Company. On July 26, 2007, Anadys announced that it and its

collaborator Novartis had decided to discontinue the development of

ANA975, a phase 1b compound for the treatment of hepatitis C virus

(HCV) infection. Following this decision, Anadys has undertaken a

strategic restructuring to focus its resources on the development of

ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B

polymerase for the treatment of HCV, and ANA773, an oral TLR7 agonist

prodrug for the treatment of certain cancers. Included within this<
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... WI (PRWEB) January 22, 2015 Dr. Greg ... the 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics ... Conference is an annual continuing education conference for health care ... and included the topic of probiotics in health. Dr. Leyer ...
(Date:1/22/2015)... 22 de enero de 2015  El Dr. Paul ... llamada a nominaciones para 2015. Este prestigioso premio reconoce ... tiene el potencial para hacer, contribuciones destacadas para la ... hasta el 15 de marzo de 2015 a través ...
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. ... company focused on advanced wound care, announces that ... tissues, have been added to the Premier, Inc. ... the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... Finn, Jr.,C.P.A. ("Finn"), Assignee of the assets of Spherics, ... all pharmaceutical,intellectual property will be sold at a sealed ... pieces of intellectual property for sale is its lead,product, ... drug that currently has more than $2 billion in ...
... Health Division, GREENFIELD, Ind., Aug. 20 Elanco, ... ), today announced that Lilly has signed,an agreement to ... (sometribove), as well as the product,s supporting operations,from Monsanto ... is increasing, outstripping supply, and consumers,are seeing rapidly rising ...
... marketing and Web development firm recently announced the launch of ... Anika Therapeutics (NASDAQ: ANIK) develops products that address the fast-growing ... worked with Pixel Bridge to plan, design, develop and implement ... ...
Cached Biology Technology:Spherics, Inc. Successful Bidder May Make MHRA Submission 2Elanco Announces Acquisition of Posilac(R) Dairy Business 2Elanco Announces Acquisition of Posilac(R) Dairy Business 3Pixel Bridge Works With Anika Therapeutics to Launch New Website 2Pixel Bridge Works With Anika Therapeutics to Launch New Website 3
(Date:12/22/2014)...  The 2014 Holiday Season may be the brightest ever ... that the long anticipated floodgates for consumer biometrics may ... smart phones, tablets, and wearable mobile devices that incorporate ... users with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... A second season in Antarctica for the Antarctic Geological ... the co-chief scientists of the program,s Southern McMurdo Sound ... passed the 1,000-meter mark in rock core pulled from ... a remarkable recovery rate of more than 98 percent. ...
... today announced,that it is collaborating with researchers at ... system. Singulex has installed the,Erenna system at Wyeth ... and has begun optimizing assays that will allow ... human blood., "Biomarkers play an important role ...
... UCLA and a team of enterprising UCLA scientists envisioning a ... In 1996, a unique collaboration of leading UCLA scientists ... Inc. and the company now stands to reap $537 ... one of the largest Los Angeles-based private biotech firms poised ...
Cached Biology News:ANDRILL's 2nd Antarctic drilling season exceeds all expectations 2ANDRILL's 2nd Antarctic drilling season exceeds all expectations 3Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design 2Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 2Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 3
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
Hepatocyte Differentiation Environment...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
...
Biology Products: